Table of Contents Author Guidelines Submit a Manuscript
Canadian Journal of Gastroenterology and Hepatology
Volume 2016, Article ID 7431838, 9 pages
http://dx.doi.org/10.1155/2016/7431838
Review Article

Association between NSAIDs and Clostridium difficile-Associated Diarrhea: A Systematic Review and Meta-Analysis

1Division of Infectious Diseases, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02115, USA
2Department of Internal Medicine, Bassett Medical Center and Columbia University College of Physicians and Surgeons, Cooperstown, NY 13326, USA
3Department of Preventive and Social Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok 10700, Thailand

Received 10 March 2015; Accepted 12 May 2015

Copyright © 2016 Nitipong Permpalung et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. L. Kyne, M. B. Hamel, R. Polavaram, and C. P. Kelly, “Health care costs and mortality associated with nosocomial diarrhea due to Clostridium difficile,” Clinical Infectious Diseases, vol. 34, no. 3, pp. 346–353, 2002. View at Publisher · View at Google Scholar · View at Scopus
  2. L. C. McDonald, M. Owings, and D. B. Jernigan, “Clostridium difficile infection in patients discharged from US short-stay hospitals, 1996–2003,” Emerging Infectious Diseases, vol. 12, no. 3, pp. 409–415, 2006. View at Publisher · View at Google Scholar · View at Scopus
  3. L. Beaugerie, A. Flahault, F. Barbut et al., “Antibiotic-associated diarrhoea and Clostridium difficile in the community,” Alimentary Pharmacology and Therapeutics, vol. 17, no. 7, pp. 905–912, 2003. View at Publisher · View at Google Scholar · View at Scopus
  4. S. Dial, J. A. C. Delaney, V. Schneider, and S. Suissa, “Proton pump inhibitor use and risk of community-acquired Clostridium difficile-associated disease defined by prescription for oral vancomycin therapy,” CMAJ, vol. 175, no. 7, pp. 745–748, 2006. View at Publisher · View at Google Scholar · View at Scopus
  5. S. Dial, J. A. C. Delaney, A. N. Barkun, and S. Suissa, “Use of gastric acid-suppressive agents and the risk of community-acquired Clostridium difficile-associated disease,” Journal of the American Medical Association, vol. 294, no. 23, pp. 2989–2995, 2005. View at Publisher · View at Google Scholar · View at Scopus
  6. S. Biswal, “Proton pump inhibitors and risk for Clostridium difficile associated diarrhea,” Biomedical Journal, vol. 37, no. 4, pp. 178–183, 2014. View at Publisher · View at Google Scholar · View at Scopus
  7. J. P. Hegarty, W. Sangster, L. R. Harris III, and D. B. Stewart, “Proton pump inhibitors induce changes in colonocyte gene expression that may affect Clostridium difficile infection.,” Surgery, vol. 156, no. 4, pp. 972–978, 2014. View at Publisher · View at Google Scholar · View at Scopus
  8. M. Romero-Gómez, E. Suárez García, and M. Castro Fernández, “Pseudomembranous colitis induced by diclofenac,” Journal of Clinical Gastroenterology, vol. 26, no. 3, article 228, 1998. View at Google Scholar
  9. A. Gentric and Y. L. Pennec, “Diclofenac-induced pseudomembranous colitis,” The Lancet, vol. 340, no. 8811, pp. 126–127, 1992. View at Publisher · View at Google Scholar · View at Scopus
  10. D. Suissa, J. A. C. Delaney, S. Dial, and P. Brassard, “Non-steroidal anti-inflammatory drugs and the risk of Clostridium difficile-associated disease,” British Journal of Clinical Pharmacology, vol. 74, no. 2, pp. 370–375, 2012. View at Publisher · View at Google Scholar · View at Scopus
  11. L. M. Soes, H. M. Holt, B. Böttiger et al., “Risk factors for Clostridium difficile infection in the community: a case-control study in patients in general practice, Denmark, 2009–2011,” Epidemiology and Infection, vol. 142, no. 7, pp. 1437–1448, 2014. View at Publisher · View at Google Scholar · View at Scopus
  12. H. Regnault, A. Bourrier, V. Lalande et al., “Prevalence and risk factors of Clostridium difficile infection in patients hospitalized for flare of inflammatory bowel disease: a retrospective assessment,” Digestive and Liver Disease, vol. 46, pp. 1086–1092, 2014. View at Publisher · View at Google Scholar · View at Scopus
  13. S. Naggie, B. A. Miller, K. B. Zuzak et al., “A case-control study of community-associated clostridium difficile infection: no role for proton pump inhibitors,” American Journal of Medicine, vol. 124, no. 3, pp. 276.e1–276.e7, 2011. View at Publisher · View at Google Scholar · View at Scopus
  14. A. R. Manges, A. Labbe, V. G. Loo et al., “Comparative metagenomic study of alterations to the intestinal microbiota and risk of nosocomial clostridum difficile-associated disease,” Journal of Infectious Diseases, vol. 202, no. 12, pp. 1877–1884, 2010. View at Publisher · View at Google Scholar · View at Scopus
  15. V. G. Loo, A.-M. Bourgault, L. Poirier et al., “Host and pathogen factors for Clostridium difficile infection and colonization,” The New England Journal of Medicine, vol. 365, no. 18, pp. 1693–1703, 2011. View at Publisher · View at Google Scholar · View at Scopus
  16. R. E. El Feghaly, J. L. Stauber, P. I. Tarr, and D. B. Haslam, “Intestinal inflammatory biomarkers and outcome in pediatric clostridium difficile infections,” Journal of Pediatrics, vol. 163, no. 6, pp. 1697.e2–1704.e2, 2013. View at Publisher · View at Google Scholar · View at Scopus
  17. D. F. Stroup, J. A. Berlin, S. C. Morton et al., “Meta-analysis of observational studies in epidemiology: a proposal for reporting,” The Journal of the American Medical Association, vol. 283, no. 15, pp. 2008–2012, 2000. View at Publisher · View at Google Scholar
  18. J. Pépin, N. Saheb, M.-A. Coulombe et al., “Emergence of fluoroquinolones as the predominant risk factor for Clostridium difficile-associated diarrhea: a cohort study during an epidemic in Quebec,” Clinical Infectious Diseases, vol. 41, no. 9, pp. 1254–1260, 2005. View at Publisher · View at Google Scholar · View at Scopus
  19. A. Stang, “Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses,” European Journal of Epidemiology, vol. 25, no. 9, pp. 603–605, 2010. View at Publisher · View at Google Scholar · View at Scopus
  20. J. P. T. Higgins, S. G. Thompson, J. J. Deeks, and D. G. Altman, “Measuring inconsistency in meta-analyses,” British Medical Journal, vol. 327, no. 7414, pp. 557–560, 2003. View at Publisher · View at Google Scholar · View at Scopus
  21. J. A. C. Sterne and M. Egger, “Funnel plots for detecting bias in meta-analysis: guidelines on choice of axis,” Journal of Clinical Epidemiology, vol. 54, no. 10, pp. 1046–1055, 2001. View at Publisher · View at Google Scholar · View at Scopus
  22. I. Etienney, L. Beaugerie, C. Viboud, and A. Flahault, “Non-steroidal anti-inflammatory drugs as a risk factor for acute diarrhoea: a case crossover study,” Gut, vol. 52, no. 2, pp. 260–263, 2003. View at Publisher · View at Google Scholar · View at Scopus
  23. G. Thiéfin and L. Beaugerie, “Toxic effects of nonsteroidal antiinflammatory drugs on the small bowel, colon, and rectum,” Joint Bone Spine, vol. 72, no. 4, pp. 286–294, 2005. View at Publisher · View at Google Scholar · View at Scopus
  24. S. Somasundaram, S. Rafi, J. Hayllar et al., “Mitochondrial damage: a possible mechanism of the ‘topical’ phase of NSAID induced injury to the rat intestine,” Gut, vol. 41, no. 3, pp. 344–353, 1997. View at Publisher · View at Google Scholar · View at Scopus